Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2017 Mar-2016 Mar-2015 Mar-2014
Growth matrix (%)        
Revenue growth (24) (13) (47) 5.44
Op profit growth (1,225) (103) (177) 1.60
EBIT growth 276 (111) 42.40 (9.10)
Net profit growth 36.10 (327) 340 (65)
Profitability ratios (%)        
OPM (8.90) 0.61 (18) 12.30
EBIT margin (14) (2.80) 22.90 8.47
Net profit margin (29) (16) 6.32 0.76
RoCE (6.60) (1.60) 13.60 8.76
RoNW (9.50) (5.40) 2.20 0.51
RoA (3.50) (2.40) 0.94 0.20
Per share ratios ()        
EPS -- -- 3.33 0.77
Dividend per share -- -- -- --
Cash EPS (12) (10) 0.10 (4.10)
Book value per share 22.90 31 38.50 36.90
Valuation ratios        
P/E -- -- 8.92 22.10
P/CEPS (2.40) (3) 289 (4.20)
P/B 1.29 0.97 0.77 0.46
EV/EBIDTA (29) 53.50 4.28 5.55
Payout (%)        
Dividend payout -- -- -- --
Tax payout (4.40) (1.20) 1.71 (42)
Liquidity ratios        
Debtor days 342 335 348 186
Inventory days 93 69.50 81.30 48.80
Creditor days (159) (172) (133) (135)
Leverage ratios        
Interest coverage 0.77 0.18 (1.70) (1.20)
Net debt / equity 1.87 1.35 0.92 1.53
Net debt / op. profit (14) 151 (3.70) 4.61
Cost breakup ()        
Material costs (80) (77) (84) (70)
Employee costs (10) (8.20) (11) (7.70)
Other costs (19) (14) (23) (10)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2017 Mar-2016 Mar-2015 Mar-2014
Revenue 65 85.30 97.70 185
yoy growth (%) (24) (13) (47) 5.44
Raw materials (52) (66) (82) (130)
As % of sales 79.90 77.40 83.60 69.90
Employee costs (6.80) (7) (11) (14)
As % of sales 10.50 8.19 11 7.68
Other costs (12) (12) (23) (19)
As % of sales 18.50 13.80 23.40 10.10
Operating profit (5.80) 0.52 (18) 22.80
OPM (8.90) 0.61 (18) 12.30
Depreciation (4.20) (4.90) (6) (9)
Interest expense (11) (13) (13) (13)
Other income 1.14 1.98 46 1.85
Profit before tax (20) (15) 8.90 2.49
Taxes 0.90 0.18 0.15 (1)
Tax rate (4.40) (1.20) 1.71 (42)
Minorities and other 0.37 1.11 -- --
Adj. profit (19) (14) 9.01 1.40
Exceptional items -- -- (2.80) --
Net profit (19) (14) 6.18 1.40
yoy growth (%) 36.10 (327) 340 (65)
NPM (29) (16) 6.32 0.76
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2017 Mar-2016 Mar-2015 Mar-2014
Profit before tax (20) (15) 8.90 2.49
Depreciation (4.20) (4.90) (6) (9)
Tax paid 0.90 0.18 0.15 (1)
Working capital 0.71 (21) (33) 33.30
Other operating items -- -- -- --
Operating cashflow (23) (41) (30) 25.80
Capital expenditure (8.60) (6.30) (13) 13.30
Free cash flow (32) (47) (43) 39
Equity raised 88.80 102 97.10 102
Investments 16.90 16.90 16.90 (17)
Debt financing/disposal (3.10) (20) (40) 39.60
Dividends paid -- -- -- --
Other items -- -- -- --
Net in cash 71.10 52 31 164
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2017 Mar-2016 Mar-2015 Mar-2014
Equity capital 22.70 18.70 18.70 18.70
Preference capital -- -- -- --
Reserves 20 39.10 53.10 50.20
Net worth 42.70 57.80 71.80 68.90
Minority interest
Debt 82.40 80.50 68.70 108
Deferred tax liabilities (net) 2.92 3.82 4 6.41
Total liabilities 128 142 145 184
Fixed assets 48.60 52.60 54.60 69.30
Intangible assets
Investments 16.90 16.90 16.90 --
Deferred tax asset (net) -- -- -- --
Net working capital 59.80 69.80 71.10 112
Inventories 16.70 16.40 16.10 27.40
Inventory Days 94.10 70.10 60.20 54
Sundry debtors 53.80 68 88.70 97.50
Debtor days 302 291 331 192
Other current assets 40.20 36.10 20.80 38.80
Sundry creditors (24) (38) (42) (42)
Creditor days 134 161 158 82.40
Other current liabilities (27) (13) (12) (9.60)
Cash 2.66 2.71 2.77 2.81
Total assets 128 142 145 184
Switch to
Consolidated
Standalone


Bafna Pharmaceuticals Ltd Report not showing data